CCMW
TVRD

Cypress Capital Management (Wyoming)’s Tvardi Therapeutics TVRD Stock Holding History

Cypress Capital Management (Wyoming)’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1
Closed -$1K – 315
2021
Q4 		$1K Buy
+1
New +$502 ﹤0.01% 274

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cypress Capital Management (Wyoming)'s TVRD Position: Q4 2024 in Review

Cypress Capital Management (Wyoming) sold out of Tvardi Therapeutics (TVRD) in Q4 2024, closing a stake of 139 shares — an estimated $1.54K sold.

Cypress Capital Management (Wyoming) first reported a position in TVRD in Q2 2018 and held it in 20 quarters. The position peaked at $3.08M in Q2 2020. 43 funds tracked by Wall St. Rank hold TVRD as of Q4 2024.

  • Cypress Capital Management (Wyoming) reported no remaining Tvardi Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cypress Capital Management (Wyoming) sold 139 Tvardi Therapeutics shares in Q4 2024, an estimated $1.54K.
  • Cypress Capital Management (Wyoming) first reported a position in Tvardi Therapeutics in Q2 2018 and held it in 20 quarters.
  • Cypress Capital Management (Wyoming)'s Tvardi Therapeutics position peaked at $3.08M in Q2 2020.
  • 43 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2024.

Based on Cypress Capital Management (Wyoming)'s 13F filing for Q4 2024, filed 23 Jan 2025.